拓新药业
(301089)
| 流通市值：31.58亿 | | | 总市值：43.92亿 |
| 流通股本：9097.63万 | | | 总股本：1.27亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 151,135,761.15 | 69,234,340.62 | 207,432,231.98 | 177,469,963.24 |
| 应收票据及应收账款 | 106,844,467.61 | 93,536,645.97 | 101,620,252.9 | 114,912,496.17 |
| 其中：应收票据 | 17,075,370.55 | 14,948,439.41 | 13,525,758.3 | 14,825,505.53 |
| 应收账款 | 89,769,097.06 | 78,588,206.56 | 88,094,494.6 | 100,086,990.64 |
| 应收款项融资 | 54,118,868.86 | 57,971,858.91 | 51,961,320.63 | 72,717,092.93 |
| 预付款项 | 5,482,106.56 | 4,488,753.79 | 9,393,961.26 | 6,239,530.91 |
| 其他应收款合计 | 158,546.13 | 141,650.37 | 146,846.99 | 70,619.3 |
| 存货 | 196,185,103.52 | 178,882,618.6 | 162,787,548.1 | 172,589,664.46 |
| 一年内到期的非流动资产 | 10,737.33 | 10,634.64 | - | - |
| 其他流动资产 | 26,712,307.61 | 21,869,904.39 | 14,734,263.32 | 40,816,013.12 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 671,009,370.01 | 677,012,163.72 | 698,317,762.17 | 734,975,599.31 |
| 非流动资产: | | | | |
| 长期应收款 | 263,250.71 | 260,732.94 | - | - |
| 长期股权投资 | - | - | 2,050,893.45 | 1,451,146.77 |
| 其他权益工具投资 | 7,946,587.22 | 7,946,587.22 | 6,921,006.21 | 6,921,006.21 |
| 固定资产 | 488,043,172.17 | 497,386,064.65 | 452,065,839.62 | 460,871,777.94 |
| 在建工程 | 378,455,334.81 | 372,681,899.44 | 376,293,699.42 | 364,148,968.75 |
| 使用权资产 | 4,229,741.03 | 4,469,160.35 | - | - |
| 无形资产 | 81,128,632.14 | 81,826,752.46 | 81,286,853.18 | 82,205,210.78 |
| 长期待摊费用 | 3,785,083.6 | 4,002,154.24 | 2,683,412.23 | 2,336,501.8 |
| 递延所得税资产 | 69,864,451.6 | 69,580,388.18 | 71,416,621.95 | 62,798,276.13 |
| 其他非流动资产 | 46,968,097.64 | 43,078,028.85 | 55,553,589.62 | 52,920,704.41 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,080,684,350.92 | 1,081,231,768.33 | 1,048,271,915.68 | 1,033,653,592.79 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,751,693,720.93 | 1,758,243,932.05 | 1,746,589,677.85 | 1,768,629,192.1 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 132,953,605.99 | 133,207,068.96 | 114,640,269.76 | 131,864,462.14 |
| 其中：应付票据 | 35,568,935.16 | 34,372,154.25 | 34,431,715.38 | 39,376,827.03 |
| 应付账款 | 97,384,670.83 | 98,834,914.71 | 80,208,554.38 | 92,487,635.11 |
| 合同负债 | 1,176,251.41 | 908,474.79 | 845,432.83 | 555,879.54 |
| 应付职工薪酬 | 8,627,924.97 | 12,562,620.81 | 8,351,747.95 | 8,295,783.62 |
| 应交税费 | 3,736,487.41 | 6,310,443.5 | 2,801,674.75 | 2,898,756.35 |
| 其他应付款合计 | 4,524,559.87 | 4,046,957.61 | 3,943,959.75 | 3,894,307.51 |
| 一年内到期的非流动负债 | 981,459.52 | 972,073.26 | - | - |
| 其他流动负债 | 10,274,989.07 | 7,316,907.08 | 7,866,449.42 | 11,139,550.43 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 162,275,278.24 | 165,324,546.01 | 138,449,534.46 | 158,648,739.59 |
| 非流动负债: | | | | |
| 租赁负债 | 3,282,898.06 | 3,251,499.38 | - | - |
| 递延收益 | 33,109,451.96 | 32,937,047.9 | 33,751,130.33 | 34,565,212.76 |
| 递延所得税负债 | 4,070,772.92 | 4,210,778.32 | 5,407,048.59 | 5,558,819.24 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 40,463,122.94 | 40,399,325.6 | 39,158,178.92 | 40,124,032 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 202,738,401.18 | 205,723,871.61 | 177,607,713.38 | 198,772,771.59 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 126,544,500 | 126,544,500 | 126,544,500 | 126,544,500 |
| 资本公积 | 621,109,964.85 | 621,109,964.85 | 621,109,964.85 | 621,109,964.85 |
| 其他综合收益 | 2,209,940.41 | 2,209,940.41 | 1,440,754.65 | 1,440,754.65 |
| 盈余公积 | 65,222,535.36 | 65,222,535.36 | 65,222,535.36 | 65,222,535.36 |
| 未分配利润 | 733,868,379.13 | 737,433,119.82 | 754,664,209.61 | 755,538,665.65 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,548,955,319.75 | 1,552,520,060.44 | 1,568,981,964.47 | 1,569,856,420.51 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,548,955,319.75 | 1,552,520,060.44 | 1,568,981,964.47 | 1,569,856,420.51 |
| 负债和股东权益合计 | 1,751,693,720.93 | 1,758,243,932.05 | 1,746,589,677.85 | 1,768,629,192.1 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-26 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |